Perspective Therapeutics, Inc. (CATX)
| Market Cap | 113.89M -27.7% |
| Revenue (ttm) | 220,000 -79.5% |
| Net Income | -122.91M |
| EPS | -1.17 |
| Shares Out | 120.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,184,418 |
| Open | 0.8600 |
| Previous Close | 0.8424 |
| Day's Range | 0.8600 - 0.9509 |
| 52-Week Range | 0.7795 - 6.1600 |
| Beta | 1.99 |
| Analysts | Strong Buy |
| Price Target | 9.71 (+930.01%) |
| Earnings Date | Nov 9, 2026 |
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2... [Read more]
Financial Performance
In 2025, Perspective Therapeutics's revenue was $884,000, a decrease of -39.20% compared to the previous year's $1.45 million. Losses were -$103.12 million, 30.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $9.71, which is an increase of 930.01% from the latest price.
News
Perspective Therapeutics price target lowered to $1 from $5 at BofA
BofA lowered the firm’s price target on Perspective Therapeutics (CATX) to $1 from $5 and keeps a Neutral rating on the shares. Perspective’s Q3 update pushed the bamzireotide pivotal timeline,…
Perspective Therapeutics reports Q3 EPS (27c), consensus (25c)
Reports Q3 revenue $20,000, consensus $47,810. “We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform,” said Thij...
Perspective Therapeutics price target lowered to $8 from $14 at Piper Sandler
Piper Sandler lowered the firm’s price target on Perspective Therapeutics (CATX) to $8 from $14 and keeps an Overweight rating on the shares after the company reported Q3 earnings and…
Perspective Therapeutics price target lowered to $8 from $11 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Perspective Therapeutics (CATX) to $8 from $11 and keeps a Buy rating on the shares after the company reported Q3…
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
SEATTLE, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics Earnings release: Q3 2026
Perspective Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Perspective Therapeutics Quarterly report: Q3 2026
Perspective Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Perspective Therapeutics presents VMT01 monotherapy data from Phase 1/2a study
Perspective Therapeutics (CATX) announced updated interim monotherapy results from its ongoing Phase 1/2a clinical trial of (212Pb)lapemelanotide zapixetar, an investigational targeted alpha therapy. ...
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics presents Phase 1/2a data for Bamzireotide Navoxetan
The company states: “Perspective Therapeutics (CATX) announced incremental data and analyses from its ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metasta...
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics price target lowered to $6 from $18 at Jones
Jones lowered the firm’s price target on Perspective Therapeutics (CATX) to $6 from $18 and keeps a Buy rating on the shares after the company presented updated Phase I/II results…
Perspective Therapeutics downgraded to Sector Perform at RBC Capital
RBC Capital analyst Leonid Timashev downgraded Perspective Therapeutics (CATX) to Sector Perform from Outperform with a price target of $4, down from $14, following the Phase 1/2a clinical trial of…
Perspective Therapeutics Transcript: Study update
VMT-α-NET showed a 72% 18-month landmark PFS across cohorts, with 37% ORR in patients whose target lesions were SSTR2-positive and 47% at 24 mCi. Safety remained favorable, and 20 mCi is the current lead dose for registrational planning.
Perspective Therapeutics Press release: Study update
Perspective Therapeutics issued a press release on October 23, 2026, disclosing material business information to investors.
Perspective Therapeutics Slides: Study update
Perspective Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Perspective Therapeutics Inc trading resumes
11:05 EDT Perspective Therapeutics (CATX) Inc trading resumes
Perspective announces interim results from Phase 1/2a VMT-a-NET trial
Perspective Therapeutics (CATX) announced new interim results from its ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type ...
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
SEATTLE, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics Inc trading halted, news pending
08:12 EDT Perspective Therapeutics (CATX) Inc trading halted, news pending
Perspective Therapeutics granted Fast Track designation for PSV359
Perspective Therapeutics (CATX) announced that the FDA granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast a...
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneer...
3 ‘Strong Buy’ Stocks Under $10 to Watch in October for 100%+ Upside
Low-priced stocks can carry high risk but also offer solid upside potential. On Wall Street, analysts currently rate three such stocks a Strong Buy: Perspective Therapeutics ($CATX), Immuneering ($IMR...